Tariff and trade policy impact
11 statements on the record across 4 companies, ordered by how much each has said. Every quote is verbatim from its call.
Pharma companies broadly describe tariff impacts as manageable rather than severe, with most emphasizing supply chain flexibility over price actions. MRK quantifies roughly $200 million in tariff costs to date mainly from US-China trade and says it will not use pricing as a lever, instead leaning on existing supply chain optimization work already underway before tariff discussions began [m2175, m2198, m2199, m2200]. GILD similarly expects tariff costs enacted to date to be manageable in 2025, aided by lighter FX headwinds [m2418]. BMY frames tariffs alongside FDA and HHS restructuring as a broader uncertainty, noting it is not overly reliant on any single country and is evaluating its global manufacturing footprint with tariffs in mind [m2286, m2306, m2299]. PFE stands apart with a concrete resolution: Bourla cites a US government agreement granting a 3 year grace period from certain tariffs tied to added US manufacturing investment, though Denton notes this will dilute 2026 guidance without affecting 2025 [m2314, m2333].
Davis said Merck expects about $200 million in costs from tariffs implemented to date, mainly between the US and China, with smaller effects from Canada and Mexico. [m2175] Davis stated Merck's global supply chain and current inventory levels position it well to navigate potential near-term impacts from additional pharmaceutical tariffs. [m2176] Davis said Merck is not using price as a lever against tariffs, focusing instead on optimizing its supply chain in response to potential further sector-specific tariffs. [m2198, m2199] Davis said much of Merck's supply chain work was already underway before the tariff discussion, aligning it with the administration's goals and positioning it to respond effectively. [m2200]
Show the 5 verbatim statements
#m2176 · 2025-04-24 · Rob Davis · STATED
“With respect to potential additional tariffs by the US, specifically on pharmaceuticals, our global supply chain and current inventory levels put us in a good position to navigate potential near-term impacts.”
#m2199 · 2025-04-24 · Rob Davis · STATED
“We are not using and do not really see price at the lever. For tariffs. Just given there's always limitations in what you can do there. So for us, it's more about how do we optimize our supply chain.”
#m2198 · 2025-04-24 · Rob Davis · STATED
“I think you're really referring to the potential for further sector-specific tariffs that could come and what we're doing.”
#m2200 · 2025-04-24 · Rob Davis · STATED
“But, again, a lot of what we're doing now, frankly, we were already underway in. So in many ways, we are aligned with what the administration is wanting to do and feel that we are in a position to be able to do that quite effectively.”
#m2175 · 2025-04-24 · Rob Davis · STATED
“The benefit from improved foreign exchange is offset in part by approximately $200 million of expected cost from tariffs implemented to date primarily between the US and China and to a lesser degree Canada and Mexico.”
Boerner flagged tariff related uncertainty alongside FDA and HHS restructuring risk as a headwind facing the company. [m2286] Elkins stated BMY is not overly reliant on any single country for its supply chain and is closely assessing the evolving tariff situation. [m2306] Boerner said the company is looking for opportunities to optimize its broad global manufacturing network with tariffs in mind. [m2299]
Show the 3 verbatim statements
#m2286 · 2025-04-24 · Christopher Boerner · STATED
“There's a lot of uncertainty, whether related to tariffs, a potential economic downturn, or restructuring at the FDA and HHS.”
#m2306 · 2025-04-24 · David Elkins · STATED
“we're not overly reliant on any single country in terms of our supply chain. The situation related to tariffs continues to evolve, we're closely assessing.”
#m2299 · 2025-04-24 · Christopher Boerner · STATED
“We have a broad global manufacturing network where we're looking for opportunities to optimize with tariffs in mind.”
Bourla said the U.S. government agreement resolved tariff uncertainty, securing a 3 year grace period from certain U.S. tariffs tied to further U.S. manufacturing investment. [m2314] Denton said this agreement will not affect 2025 guidance but is expected to dilute the 2026 financial outlook. [m2333]
Show the 2 verbatim statements
#m2333 · 2025-11-04 · David Denton · STATED · by 2026
“The agreement has no impact on our 2025 guidance, but we expect a dilutive impact to our 2026 financial outlook.”
#m2314 · 2025-11-04 · Albert Bourla · STATED
“Our landmark agreement with the U.S. government was an important milestone because it removed uncertainty on 2 critical policy fronts. We successfully addressed the administration's call to lower prescription drug costs and align prices with those in other developed countries, and we will have a 3-year grace period from certain U.S. tariffs with our commitment to further invest in manufacturing in the U.S.”
CFO Andrew Dickinson stated that tariffs enacted to date could raise indirect costs but are expected to be manageable in 2025, partly due to lighter FX headwinds than previously expected. [m2418]
Show the 1 verbatim statement
#m2418 · 2025-04-24 · Andrew Dickinson · STATED · by 2025
“As we reflect on the tariffs that have been enacted to date, these could increase some of our indirect costs, but are expected to be manageable in 2025, in part due to potentially lighter FX headwinds than previously expected.”
OPEN is an unresolved commitment on the clock; STATED is on the record without a checkable bar and is never counted or scored. Method: methodology.